DLL4 and neoplasm: Interestingly, despite clear blood vessel remodeling, Dll4 blockade did not have activity as a single agent in this sunitinib resistant PDX model, but it potentiated the anti-tumor effect of ziv-aflibercept by inducing tumor regression.